Nuvalent Inc - Class A — 財務諸表 (NASDAQ:NUVL) | MetaTrader

チャート全体を表示

ニュース

Nuvation Bioの決算に注目、Ibtroziの勢いが試される局面

Nuvation Bio earnings in focus: Ibtrozi momentum faces test

Does Nuvalent (NUVL) Have the Potential to Rally 37.26% as Wall Street Analysts Expect?

Nuvalent、第4四半期の損失を報告、肺がん治療薬のFDA判断を待つ

Nuvalent reports Q4 loss, awaits FDA decision on lung cancer drug

Drugmakers turn to AI to speed trials, regulatory submissions

ニューバレント社株、52週間高値の112.89ドルを記録

Nuvalent Inc stock hits 52-week high at 112.89 USD

FDAがNuvalentのROS1陽性NSCLC治療薬の新薬申請を受理

FDA accepts Nuvalent’s NDA for ROS1-positive NSCLC treatment

Nuvalent (NUVL) chief legal officer Miller sells $676k in stock

Nuvalent CSO Pelish sells shares worth $501,752